Colorectal Patients Offered New Resource to Help Navigate Treatment Process
- Patient Advocate Foundation and Amgen Oncology Launch Colorectal CareLine -
NEWPORT NEWS, Va. & THOUSAND OAKS, Calif., Nov 29, 2006 (BUSINESS WIRE) -- The Patient Advocate Foundation (PAF), with support from Amgen
(Nasdaq:AMGN), is pleased to announce the launch of the Colorectal
CareLine (CCL). The national toll free telephone hotline is designed
to offer assistance to all colorectal cancer patients and healthcare
providers seeking educational resources, direct assistance with access
to care issues and/or financial aid for select patient needs,
including lodging, transportation, childcare and other expenses
associated with out-of-town treatment. The hotline can be accessed at
1-866-657-8634 or patients may visit www.colorectalcareline.org.
Staffed by a dedicated team of multilingual clinical case managers
with nursing and social work experience, the Colorectal CareLine
offers personal case management services, including the dissemination
of disease information, direction on how to obtain financial
assistance, availability of clinical trials, and guidance in managing
the reimbursement process.
"Navigating the reimbursement system in order to obtain prescribed
care and accessing available financial and educational resources
following a diagnosis of colorectal cancer can be confusing and
overwhelming for patients," said Beth Darnley, chief program officer
at the Patient Advocate Foundation. "Options such as the Colorectal
CareLine offer a centralized resource for information and direct
support to help patients and their healthcare providers manage this
The Colorectal CareLine is the latest addition to PAF's portfolio
of patient services. The Foundation's existing programs include direct
case management services, the National Hispanic/Latino, African
American and Senior Outreach initiatives, Hematologic Cancer Education
Program and the national Livestrong SurvivorCare partnership.
"Amgen is proud to support PAF's Colorectal CareLine," said
Cynthia Schwalm, vice president and general manager, oncology at
Amgen. "The toll free number will help ensure that colorectal cancer
patients have the information and tools they need to get through their
In an effort to spread the word about the Colorectal CareLine to
the community, PAF will partner with several advocacy and patient
groups to ensure the patients that need these services learn about
them. The Colorectal CareLine is funded by a donation from Amgen.
Patient Advocate Foundation
Patient Advocate Foundation is a national non-profit organization
that seeks to safeguard patients through effective mediation assuring
access to care, maintenance of employment and preservation of their
More information may be obtained at www.patientadvocate.org or by
calling (800) 532-5274.
About Colorectal Cancer
Colorectal cancer is the third most common cancer diagnosed in men
and women--and the second leading cause of cancer death - in the
United States (after lung cancer). The American Cancer Society
estimates that about 146,940 new cases of colon cancer and 41,930 new
cases of rectal cancer will be diagnosed in 2006. It has been
estimated that 56,370 people will die from colorectal cancer in 2006.
That means that one person in the United States dies of colorectal
cancer every 9.3 minutes.
Amgen discovers, develops and delivers innovative human
therapeutics. A biotechnology pioneer since 1980, Amgen was one of the
first companies to realize the new science's promise by bringing safe
and effective medicines from lab, to manufacturing plant, to patient.
Amgen therapeutics have changed the practice of medicine, helping
millions of people around the world in the fight against cancer,
kidney disease, rheumatoid arthritis, and other serious illnesses.
With a broad and deep pipeline of potential new medicines, Amgen
remains committed to advancing science to dramatically improve
people's lives. To learn more about our pioneering science and our
vital medicines, visit www.amgen.com.
Beth Darnley, 757-952-1365
Molly Cogan, 916-444-3934
Trish Hawkins, 805-447-5631 (media)
Arvind Sood, 805-447-1060 (investors)